Approval for introduction of a new instrument model, the immulite 2000 xpi analyzer, as a new family member of the currently approved immulite 2000 analyzer, to be used with the currently approved immulite 2000 anti-hbc igm assay.  The device, as modified, will be marketed under the trade name immulite 2000 xpi anti-hbc igm assay and is indicated for in vitro diagnostic use for the laboratory diagnosis of acute or recent (usually within 6 months) hepatitis b virus infections in conjunction with other serological and clinical information.